ClinicalTrials.gg
CompletedNCT06432088Updated May 29, 2025Results posted

Safety and Feasibility of Liver Retraction With the Levita Magnetic Surgical System: Extended Magnetic Grasper Device

An interventional study of Extended Magnetic Grasper Device in Bariatric Surgery Candidate and Hiatal Hernia, sponsored by Levita Magnetics. Completed at 1 site in Chile. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-29.

Sponsored by Levita Magnetics · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to evaluate the safety and effectiveness of the Extended Magnetic Grasper Device in patients undergoing bariatric and/or hiatal hernia procedures, as a liver retractor grasping the liver and/or the tissue surrounding the crus of the diaphragm.

Read the detailed description

The purpose of this study is to evaluate the safety and effectiveness of the Levita Magnetic Surgical System Version 2 in patients undergoing bariatric and/or hiatal hernia procedures.

02

Conditions studied

  • Bariatric Surgery Candidate
  • Hiatal Hernia

Browse trials for

03

In context

Hernia, Hiatal

87 studies on the registry are indexed under Hernia, Hiatal; 27 are open to participants now.

This study's enrollment of 30 is below the median of 100 across 56 interventional studies indexed under Hernia, Hiatal.

Browse Hernia, Hiatal studies →

Lead sponsor

Levita Magnetics is the lead sponsor of 10 studies on the registry; 1 is open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At least 18 years of age.
  • Scheduled to undergo elective bariatric and/or hiatal hernia procedures.
  • Willing and able to provide a written Form (ICF) to participate in the study prior to any study required procedures.

Exclusion criteria

Exclusion Criteria:

  • Individuals with pacemakers, defibrillators, or other electromedical implants.
  • Individuals with ferromagnetic implants.
  • (ASA) score of III or IV.
  • Significant comorbidities: cardiovascular, neuromuscular, , and urological disease (renal failure).
  • Clinical history of impaired coagulation confirmed by abnormal blood tests.
  • Individuals has signs of hepatic abnormality (e.g.: cirrhosis, liver failure, increase in liver enzymes, etc.).
  • Anatomical abnormality or disease of intended target tissue noted after initiation of index procedure that would prevent device use.
  • Pregnant or wishes to become pregnant during the length of study participation.
  • Individual is not likely to comply with the follow-up evaluation schedule.
  • Participating in a clinical trial of another drug or device.
  • Prisoner or under incarceration.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Extended Magnetic Grasper Device

    Evaluation of the safety and effectiveness of the Extended Magnetic Grasper Device in patients undergoing bariatric and/or hiatal hernia procedures, as a liver retractor grasping the liver and/or the tissue surrounding the crus of the diaphragm.

    Device: Extended Magnetic Grasper Device

Interventions

  • DeviceExtended Magnetic Grasper Device

    The purpose of this study is to evaluate the safety and effectiveness of the Extended Magnetic Grasper Device in patients undergoing bariatric and/or hiatal hernia procedures, as a liver retractor grasping the liver and/or the tissue surrounding the crus of the diaphragm.

06

What researchers measure

Primary outcomes

  1. Number of Device Related Adverse Events

    All adverse events will be captured and reported. Adverse events will be summarized by relatedness to the device and/or procedure, seriousness and level of severity.

    Time frame: 30 days

  2. Mobilization Requiring Additional Retractors

    Ability to adequately mobilize the liver to achieve an effective exposure of the target tissue. Adequate mobilization is not achieved if it is necessary to use another liver retractor during the procedure.

    Time frame: 1 day

07

Results

Posted May 29, 2025

Participant flow

Participant flow — Overall Study
MilestoneExtended Magnetic Grasper Device
Started30
Completed30
Not completed0

Outcome measures

PrimaryNumber of Device Related Adverse Events

All adverse events will be captured and reported. Adverse events will be summarized by relatedness to the device and/or procedure, seriousness and level of severity.

Time frame:
30 days
Reported as:
Number · Device related adverse events
Number of Device Related Adverse Events
Device related adverse eventsExtended Magnetic Grasper Device
Number of Device Related Adverse Events0
PrimaryMobilization Requiring Additional Retractors

Ability to adequately mobilize the liver to achieve an effective exposure of the target tissue. Adequate mobilization is not achieved if it is necessary to use another liver retractor during the procedure.

Time frame:
1 day
Reported as:
Number · Procedures w/ additional retractors
Mobilization Requiring Additional Retractors
Procedures w/ additional retractorsExtended Magnetic Grasper Device
Mobilization Requiring Additional Retractors0

Adverse events

Collected over Adverse events (AE) and serious adverse events (SAEs) were recorded from index procedure through study exit (30 day follow up).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Extended Magnetic Grasper Device0/30 (0%)0/30 (0%)14/30 (46.7%)
Most frequent other events
Most frequent other events
EventExtended Magnetic Grasper Device
PetechiaSkin and subcutaneous tissue disorders7/30
Ecchymosis in Surgical IncisionSkin and subcutaneous tissue disorders5/30
Liver Capsule Minor AbrasionSurgical and medical procedures5/30
Sinus TachycardiaCardiac disorders1/30
Transverse Colon InjuryGastrointestinal disorders1/30
Atrioventricular BlockCardiac disorders1/30

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Extended Magnetic Grasper Device
<=18 years0
Between 18 and 65 years28
>=65 years2
Sex: Female, Male
Sex: Female, Male(Participants)Extended Magnetic Grasper Device
Female22
Male8
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Extended Magnetic Grasper Device
Hispanic or Latino30
Not Hispanic or Latino0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Extended Magnetic Grasper Device
Chile30
BMI
BMI(kg/m²)Extended Magnetic Grasper Device
Mean39.09 ± 5.46
08

Study locations

1 site
  • Hospital Santiago Oriente Dr. Luis Tisné Brousse
    Santiago, Metropolitana, Chile
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06432088
Lead sponsor
Levita Magnetics
Responsible party
Sponsor
First posted
May 29, 2024
Start date
May 13, 2024
Primary completion
Sep 28, 2024
Completion
Sep 30, 2024
Results posted
May 29, 2025
Last update
May 29, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion